Beacon Biosignals Raises Over $97M in Series B Funding

The Boston-based biotech company expands its Series B financing round.

Apr. 6, 2026 at 12:33pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of sleek, geometric medical devices and instruments in shades of silver, white, and blue, conceptually representing the advanced technology of Beacon Biosignals' neurophysiological data analytics platform.Beacon Biosignals' expanded Series B funding will accelerate the development of its cutting-edge neurophysiological data analytics technology.Boston Today

Beacon Biosignals, a Boston-based biotech company, has announced an extension of its Series B financing round, bringing the total raised to over $97 million. The additional funding will support the company's continued development of its advanced neurophysiological data analytics platform.

Why it matters

The successful Series B raise demonstrates investor confidence in Beacon Biosignals' technology and its potential to transform neurological diagnostics and treatment. As a leader in the growing field of biomedical signal processing, the company's expanded funding will allow it to accelerate product development and expand its reach in the healthcare market.

The details

Beacon Biosignals' Series B financing was upsized from its initial $75 million close to over $97 million, reflecting strong investor demand. The additional capital will be used to further develop the company's proprietary platform, which leverages advanced machine learning and signal processing techniques to extract clinically relevant insights from complex neurophysiological data.

  • Beacon Biosignals announced the extension of its Series B financing on April 6, 2026.

The players

Beacon Biosignals

A Boston-based biotech company that develops advanced neurophysiological data analytics platforms.

Got photos? Submit your photos here. ›

What’s next

Beacon Biosignals plans to use the additional Series B funding to accelerate the development and commercialization of its neurophysiological data analytics platform, with the goal of bringing innovative diagnostic and treatment solutions to the healthcare market.

The takeaway

Beacon Biosignals' successful Series B financing round underscores the growing demand for innovative biomedical technologies that can unlock the power of complex neurological data. The company's expanded funding will enable it to further advance its platform and solidify its position as a leader in the field of neurophysiological data analytics.